Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PTPRA | P18433 | 1/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31109684 | 1.00 | TLR2 (0.47) | TLR2MMP2MMP9SMN1; SMN2HRH1 | |
| SCHEMBL28231017 | 1.00 | TLR2 (0.47) | TLR2MMP2MMP9SMN1; SMN2HRH1 | |
| SCHEMBL5139242 | 0.84 | PTPRA (0.48) | SMN1; SMN2NPC1RAB9APOLBLMNA | |
| SCHEMBL27585986 | 0.82 | TLR2 (0.49) | TLR2SMN1; SMN2HRH1MEN1KMT2A | |
| SCHEMBL3650068 | 0.80 | TLR2 (0.67) | TLR2MMP2MMP9 | |
| SCHEMBL28030840 | 0.80 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9APOLBLMNA | |
| SCHEMBL1976380 | 0.80 | TLR2 (0.67) | TLR2MMP2MMP9 | |
| SCHEMBL28030272 | 0.80 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9APOLBLMNA | |
| SCHEMBL8484330 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9APOLBLMNA | |
| SCHEMBL6949056 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9APOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234202-A1 | Non-natural amino acids and neurotensin analogues | ARGOLYN BIOSCIENCES, INC. | 2008-09-25 | — | — | US | disclosed |
| WO-2008105759-A1 | METHODS FOR SYNTHESIS OF MODIFIED PEPTIDES | ARGOLYN BIOSCIENCE, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234202-A1 | Non-natural amino acids and neurotensin analogues | NGLY1, NTSR1, NTSR2 | TLR2 3104/4885MMP2 3975/4885MMP9 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.